Pear Therapeutics Launches Somryst Prescription Insomnia App Through Direct-To-Consumer Telehealth Model

On November 17, 2020, Pear Therapeutics launched sales of Somryst, its prescription digital therapeutic (DPT) application for chronic insomnia, through an end-to-end direct-to-consumer telehealth platform that functions as a consumer service center for DPTs, PearConnect. The virtual care experience provides telemedicine visits with a physician who can evaluate the consumer, prescribe Somryst, and provide access to a case worker from PearConnect who will help the consumer download the app and start treatment.

The U.S. Food and Drug Administration (FDA) granted authorization for Somryst in March 2020. Somryst is intended to treat chronic insomnia in people . . .